TNFSF9 and hepatocellular carcinoma: Ad5-PC is a novel platform engineered to express a bispecific PD-1/CD137L fusion protein, promoting sustained cytotoxic T lymphocytes (CTLs) persistence and heightened immune activation, ultimately resulting in durable tumor control in hepatocellular carcinoma (HCC) (51).